Search

Your search keyword '"Cornel, Jan H."' showing total 11 results
Start Over Author "Cornel, Jan H." Publisher massachusetts medical society
11 results on '"Cornel, Jan H."'

1. Lenient versus strict rate control in patients with atrial fibrillation

Author

Van Gelder, Isabelle C., Groenveld, Hessel F., Crijns, Harry J/G.M., Tuininga, Ype S., Tijssen, Jan G.P., Alings, A. Marco, Hillege, Hans L., Bergsma-Kadijk, Johanna A., Cornel, Jan H., Kamp, Otto, Tukkie, Raymond, Bosker, Hans A., Van Veldhuisen, Dirk J., and Van den Berg, Maarten

Subjects
Atrial fibrillation -- Health aspects, Cardiovascular diseases -- Care and treatment, Heart beat -- Measurement
Abstract

A study was conducted to evaluate and compare lenient rate control as against strict rate control as a form of treatment in patients with atrial fibrillation. Results indicated that in patients with permanent atrial fibrillation, both types of rate control were found to be equally effective with lenient rate control being easier to achieve.

Published
2010

2. Rosuvastatin in older patients with systolic heart failure

Author

Kjekshus, John, Apetrei, Eduard, Barrios, Vinencio, Bohm, Michael, Cleland, John G.F., Cornel, Jan H., Dunselman, Peter, Fonseca, Candida, Goudev, Assen, Grande, Peer, Gullestad, Lars, Hjalmarson, Ake, Hradec, Jaromir, Janosi, Andras, Kamensky, Gabriel, Komajda, Michel, Korewicki, Jerzy, Kuusi, Timo, Mach, Francois, Mareev, Vyacheslav, McMurray, John J.V., Ranjith, Naresh, Schaufelberger, Maria, Vanhaecke, Johan, van Veldhuisen, Dirk J., Waagstein, Finn, Wedel, Hans, and Wikstrand, John

Subjects
Heart failure -- Drug therapy, Placebos -- Comparative analysis, Rosuvastatin -- Dosage and administration, Rosuvastatin -- Comparative analysis
Abstract

The results of clinical trial conducted by comparing rosuvastatin with placebo in elderly patients with systolic, ischemic heart failure are reported. Rosuvastatin was not effective as a therapy for heart failure, but was found to play significant role in reducing levels of both low-density lipoprotein cholesterol and high-sensitivity C-reactive protein.

Published
2007

3. Colchicine in Patients with Chronic Coronary Disease

Author

Nidorf, Stefan M., primary, Fiolet, Aernoud T.L., additional, Mosterd, Arend, additional, Eikelboom, John W., additional, Schut, Astrid, additional, Opstal, Tjerk S.J., additional, The, Salem H.K., additional, Xu, Xiao-Fang, additional, Ireland, Mark A., additional, Lenderink, Timo, additional, Latchem, Donald, additional, Hoogslag, Pieter, additional, Jerzewski, Anastazia, additional, Nierop, Peter, additional, Whelan, Alan, additional, Hendriks, Randall, additional, Swart, Henk, additional, Schaap, Jeroen, additional, Kuijper, Aaf F.M., additional, van Hessen, Maarten W.J., additional, Saklani, Pradyot, additional, Tan, Isabel, additional, Thompson, Angus G., additional, Morton, Allison, additional, Judkins, Chris, additional, Bax, Willem A., additional, Dirksen, Maurits, additional, Alings, Marco, additional, Hankey, Graeme J., additional, Budgeon, Charley A., additional, Tijssen, Jan G.P., additional, Cornel, Jan H., additional, and Thompson, Peter L., additional

Published
2020
Full Text
View/download PDF

4. Ticagrelor in Patients with Stable Coronary Disease and Diabetes

Author

Steg, P. Gabriel, primary, Bhatt, Deepak L., additional, Simon, Tabassome, additional, Fox, Kim, additional, Mehta, Shamir R., additional, Harrington, Robert A., additional, Held, Claes, additional, Andersson, Marielle, additional, Himmelmann, Anders, additional, Ridderstråle, Wilhelm, additional, Leonsson-Zachrisson, Maria, additional, Liu, Yuyin, additional, Opolski, Grzegorz, additional, Zateyshchikov, Dmitry, additional, Ge, Junbo, additional, Nicolau, José C., additional, Corbalán, Ramón, additional, Cornel, Jan H., additional, Widimský, Petr, additional, and Leiter, Lawrence A., additional

Published
2019
Full Text
View/download PDF

5. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Author

Ridker, Paul M, primary, Everett, Brendan M., additional, Thuren, Tom, additional, MacFadyen, Jean G., additional, Chang, William H., additional, Ballantyne, Christie, additional, Fonseca, Francisco, additional, Nicolau, Jose, additional, Koenig, Wolfgang, additional, Anker, Stefan D., additional, Kastelein, John J.P., additional, Cornel, Jan H., additional, Pais, Prem, additional, Pella, Daniel, additional, Genest, Jacques, additional, Cifkova, Renata, additional, Lorenzatti, Alberto, additional, Forster, Tamas, additional, Kobalava, Zhanna, additional, Vida-Simiti, Luminita, additional, Flather, Marcus, additional, Shimokawa, Hiroaki, additional, Ogawa, Hisao, additional, Dellborg, Mikael, additional, Rossi, Paulo R.F., additional, Troquay, Roland P.T., additional, Libby, Peter, additional, and Glynn, Robert J., additional

Published
2017
Full Text
View/download PDF

6. Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization

Author

Roe, Matthew T., primary, Armstrong, Paul W., additional, Fox, Keith A.A., additional, White, Harvey D., additional, Prabhakaran, Dorairaj, additional, Goodman, Shaun G., additional, Cornel, Jan H., additional, Bhatt, Deepak L., additional, Clemmensen, Peter, additional, Martinez, Felipe, additional, Ardissino, Diego, additional, Nicolau, Jose C., additional, Boden, William E., additional, Gurbel, Paul A., additional, Ruzyllo, Witold, additional, Dalby, Anthony J., additional, McGuire, Darren K., additional, Leiva-Pons, Jose L., additional, Parkhomenko, Alexander, additional, Gottlieb, Shmuel, additional, Topacio, Gracita O., additional, Hamm, Christian, additional, Pavlides, Gregory, additional, Goudev, Assen R., additional, Oto, Ali, additional, Tseng, Chuen-Den, additional, Merkely, Bela, additional, Gasparovic, Vladimir, additional, Corbalan, Ramon, additional, Cinteză, Mircea, additional, McLendon, R. Craig, additional, Winters, Kenneth J., additional, Brown, Eileen B., additional, Lokhnygina, Yuliya, additional, Aylward, Philip E., additional, Huber, Kurt, additional, Hochman, Judith S., additional, and Ohman, E. Magnus, additional

Published
2012
Full Text
View/download PDF

7. Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes

Author

Tricoci, Pierluigi, primary, Huang, Zhen, additional, Held, Claes, additional, Moliterno, David J., additional, Armstrong, Paul W., additional, Van de Werf, Frans, additional, White, Harvey D., additional, Aylward, Philip E., additional, Wallentin, Lars, additional, Chen, Edmond, additional, Lokhnygina, Yuliya, additional, Pei, Jinglan, additional, Leonardi, Sergio, additional, Rorick, Tyrus L., additional, Kilian, Ann M., additional, Jennings, Lisa H.K., additional, Ambrosio, Giuseppe, additional, Bode, Christoph, additional, Cequier, Angel, additional, Cornel, Jan H., additional, Diaz, Rafael, additional, Erkan, Aycan, additional, Huber, Kurt, additional, Hudson, Michael P., additional, Jiang, Lixin, additional, Jukema, J. Wouter, additional, Lewis, Basil S., additional, Lincoff, A. Michael, additional, Montalescot, Gilles, additional, Nicolau, José Carlos, additional, Ogawa, Hisao, additional, Pfisterer, Matthias, additional, Prieto, Juan Carlos, additional, Ruzyllo, Witold, additional, Sinnaeve, Peter R., additional, Storey, Robert F., additional, Valgimigli, Marco, additional, Whellan, David J., additional, Widimsky, Petr, additional, Strony, John, additional, Harrington, Robert A., additional, and Mahaffey, Kenneth W., additional

Published
2012
Full Text
View/download PDF

8. Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome

Author

Alexander, John H., primary, Lopes, Renato D., additional, James, Stefan, additional, Kilaru, Rakhi, additional, He, Yaohua, additional, Mohan, Puneet, additional, Bhatt, Deepak L., additional, Goodman, Shaun, additional, Verheugt, Freek W., additional, Flather, Marcus, additional, Huber, Kurt, additional, Liaw, Danny, additional, Husted, Steen E., additional, Lopez-Sendon, Jose, additional, De Caterina, Raffaele, additional, Jansky, Petr, additional, Darius, Harald, additional, Vinereanu, Dragos, additional, Cornel, Jan H., additional, Cools, Frank, additional, Atar, Dan, additional, Leiva-Pons, Jose Luis, additional, Keltai, Matyas, additional, Ogawa, Hisao, additional, Pais, Prem, additional, Parkhomenko, Alexander, additional, Ruzyllo, Witold, additional, Diaz, Rafael, additional, White, Harvey, additional, Ruda, Mikhail, additional, Geraldes, Margarida, additional, Lawrence, Jack, additional, Harrington, Robert A., additional, and Wallentin, Lars, additional

Published
2011
Full Text
View/download PDF

9. Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction.

Author

Gibson CM, Duffy D, Korjian S, Bahit MC, Chi G, Alexander JH, Lincoff AM, Heise M, Tricoci P, Deckelbaum LI, Mears SJ, Nicolau JC, Lopes RD, Merkely B, Lewis BS, Cornel JH, Trebacz J, Parkhomenko A, Libby P, Sacks FM, Povsic TJ, Bonaca M, Goodman SG, Bhatt DL, Tendera M, Steg PG, Ridker PM, Aylward P, Kastelein JJP, Bode C, Mahaffey KW, Nicholls SJ, Pocock SJ, Mehran R, and Harrington RA

Subjects
Aged, Female, Humans, Male, Middle Aged, Cardiovascular Diseases etiology, Cardiovascular Diseases metabolism, Cardiovascular Diseases mortality, Cardiovascular Diseases prevention & control, Coronary Artery Disease drug therapy, Coronary Artery Disease complications, Double-Blind Method, Infusions, Intravenous, Kaplan-Meier Estimate, Recurrence, Secondary Prevention, Stroke prevention & control, Risk Factors, Apolipoprotein A-I administration & dosage, Apolipoprotein A-I blood, Lipoproteins, HDL blood, Lipoproteins, HDL metabolism, Myocardial Infarction complications, Myocardial Infarction drug therapy, Myocardial Infarction metabolism, Myocardial Infarction mortality
Abstract

Background: Cardiovascular events frequently recur after acute myocardial infarction, and low cholesterol efflux - a process mediated by apolipoprotein A1, which is the main protein in high-density lipoprotein - has been associated with an increased risk of cardiovascular events. CSL112 is human apolipoprotein A1 derived from plasma that increases cholesterol efflux capacity. Whether infusions of CSL112 can reduce the risk of recurrent cardiovascular events after acute myocardial infarction is unclear., Methods: We conducted an international, double-blind, placebo-controlled trial involving patients with acute myocardial infarction, multivessel coronary artery disease, and additional cardiovascular risk factors. Patients were randomly assigned to receive either four weekly infusions of 6 g of CSL112 or matching placebo, with the first infusion administered within 5 days after the first medical contact for the acute myocardial infarction. The primary end point was a composite of myocardial infarction, stroke, or death from cardiovascular causes from randomization through 90 days of follow-up., Results: A total of 18,219 patients were included in the trial (9112 in the CSL112 group and 9107 in the placebo group). There was no significant difference between the groups in the risk of a primary end-point event at 90 days of follow-up (439 patients [4.8%] in the CSL112 group vs. 472 patients [5.2%] in the placebo group; hazard ratio, 0.93; 95% confidence interval [CI], 0.81 to 1.05; P = 0.24), at 180 days of follow-up (622 patients [6.9%] vs. 683 patients [7.6%]; hazard ratio, 0.91; 95% CI, 0.81 to 1.01), or at 365 days of follow-up (885 patients [9.8%] vs. 944 patients [10.5%]; hazard ratio, 0.93; 95% CI, 0.85 to 1.02). The percentage of patients with adverse events was similar in the two groups; a higher number of hypersensitivity events was reported in the CSL112 group., Conclusions: Among patients with acute myocardial infarction, multivessel coronary artery disease, and additional cardiovascular risk factors, four weekly infusions of CSL112 did not result in a lower risk of myocardial infarction, stroke, or death from cardiovascular causes than placebo through 90 days. (Funded by CSL Behring; AEGIS-II ClinicalTrials.gov number, NCT03473223.)., (Copyright © 2024 Massachusetts Medical Society.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results